Backed by a proven network of leading trial sites across Australia and New Zealand.
A track-record of delivering for a global client-base for more than 20 years.
Australia’s regulatory framework is the fastest in the world for early-phase clinical trials.
Deploy the latest solutions to maximise the value of your study data and deliver real-time visibility on your study progress.
Avance Clinical is an Australian owned Contract Research Organisation (CRO) that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years. Avance Clinical specialises in supporting biotech companies with their early phase clinical trials leveraging the world-class early phase clinical trials ecosystem in Australia.
Avance Clinical has a global reputation for outstanding service to our biotech clients in the United States, United Kingdom, Japan, China, South Korea, Taiwan, France and Germany.
As a leading Australian CRO, with extensive experience across all phases of clinical research, complemented with our full suite of in-house clinical research services, we can ensure your trials are delivered on time and on budget as a certified contract research organisation.
Avance Clinical Wins Frost & Sullivan “2020 Asia-Pacific CRO Market Leadership Award
“Within Asia-Pacific’s highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials.
The company offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance. Avance Clinical offers a real size match for biotechs that means better mission understandings and stronger customer service compared to some of the larger CROs.”
Nidhi Jalali,
Analyst Best Practices, Frost & Sullivan
“We aim to give clients unparalleled service to optimise the timely and cost effective completion of projects. It’s as simple as that”
Yvonne Lungershausen,
Chief Executive Officer
Australia has been recognized globally for its handling of the COVID-19 pandemic with strict quarantine systems and advanced contact tracing, resulting in low numbers of cases and deaths. Therefore we have seen a dramatic increase in the number of USA sponsors moving their trials to Australia.
“We are excited to welcome Avance Clinical to our global community of Argus customers,” said Bruce Palsulich, Vice President, Safety Product Strategy, Oracle Health Sciences.
“Argus provides proven compliance with continuously changing worldwide regulations, and its built-in automations, integrations, and usability significantly reduce manual work and maximize efficiency. We are pleased that Avance Clinical has chosen to standardize on Argus for safety case management.”
Avance Clinical has positioned itself as a global leader in early phase clinical trials by developing innovative strategies and approaches to initial phase development. It helps global biotech companies set up clinic and achieve proof of concept faster with a data package that stands up to the scrutiny of global regulators. The company is well reputed for proven support of the biotech industry by providing scientific and regulatory expertise to help develop the best strategy to achieve clinical trial outcomes in the most time- efficient manner.
Australia’s CRO for biotechs, Avance Clinical, deep dives into the patient recruitment landscape identifying the mechanisms and processes that deliver exceptional patient recruitment for early phase trials in Australia.
Avance Clinical is pleased to share the news that their client Atossa Therapeutics (NASDAQ: ATOS) has announced completion of enrollment in its Phase 1 clinical study.
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.
Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs.
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that client Atossa Therapeutics has announced a positive interim safety assessment from the second cohort of healthy participants in the Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray.
Avance Clinical has formed a dedicated scientific and regulatory affairs service, ClinicReady by Avance Clinical, in response to increased demand from biotechs for preclinical study management and scientific and regulatory advice to take their products to first-in-human trials.
The highly regarded Avance Clinical scientific and regulatory team, which has been advising biotech clients on their drug development for more than 20 years, is now a dedicated ClinicReady service under the Avance Clinical banner.
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis.
Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)
